Pacira Biosciences, Inc. (PCRX)

Over the past six months, Pacira Biosciences, Inc.'s stock price has been impacted by several events. Activist investor pressure from DOMA Perpetual Capital Management advocated for board changes and a potential sale process. The company reported a Q4 2025 earnings miss and lowered its 2025 revenue forecast. Zacks Research downgraded PCRX to a "strong sell," but Pacira BioSciences shares closed higher in after-hours trading in March 2026. Fears regarding EXPAREL patent erosion due to a court ruling involving eVenus contributed to the stock trading at distressed levels. The NOPAIN Act introduced a significant reimbursement tailwind. The company completed a $150.05 million buyback totaling 5,932,106 shares since May 2025. Pacira presented real-world data at the ORS 2026 Annual Meeting showing EXPAREL reduced total cost of care versus standard alternatives in orthopedic procedures.

Significant demand seasonality is not explicitly indicated for Pacira Biosciences' products. Demand for medical treatments addressing postsurgical pain, osteoarthritis, and chronic nerve pain is generally driven by ongoing healthcare needs, scheduled medical procedures, and the prevalence of chronic conditions, rather than strong seasonal fluctuations.

Pacira Biosciences, Inc. is a pharmaceutical company focused on developing, manufacturing, and commercializing non-opioid pain management and regenerative health solutions. The company's core business revolves around products that manage pain without relying on opioid medications, including postsurgical local and regional analgesia, osteoarthritis knee pain management, and device-based cryoneurolysis for peripheral nerve pain. Major commercialized products include EXPAREL, a long-acting local analgesic; ZILRETTA, an extended-release, intra-articular corticosteroid injection; and iovera°, a handheld device for drug-free pain control. Pacira is also advancing PCRX-201, a locally administered gene therapy in Phase 2 clinical development for osteoarthritis of the knee.

Pacira Biosciences, Inc. primarily focuses its operations and sales within the United States, with corporate headquarters in Brisbane, California, and another corporate office in Tampa, Florida. The company has expanded its geographic reach through a commercial partnership with LG Chem, granting them exclusive rights to commercialize EXPAREL in select Asia-Pacific markets.

Pacira Biosciences' brand reputation has been influenced by both positive developments and challenges. The company is recognized as an "industry leader" in delivering non-opioid pain therapies and was highlighted by Zacks Research as a top pharmaceutical stock to buy in March 2026. The company also presented real-world data demonstrating EXPAREL's ability to reduce total cost of care in orthopedic procedures. However, the company has faced scrutiny due to activist investor pressure, a Q4 2025 earnings miss, a lowered 2025 revenue forecast, and fears surrounding potential patent erosion for EXPAREL.

Pacira Biosciences, Inc. has a significant level of institutional ownership, ranging from 94.14% to 99.73% of its stock. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc, and Doma Perpetual Capital Management LLC. Individual investors and company insiders also hold shares, with insiders holding 6.40% of the stock. There have been recent insider sales, with insiders selling $157,656.00 in company stock in the past three months.